Jonaer Barnes News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jonaer barnes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jonaer Barnes Today - Breaking & Trending Today
innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. After successfully completing a Phase 2a proof-of-concept trial for the treatment of NASH, which met its primary endpoint and study objectives, for ....
News Category Global Banking & Finance Reviews Allterco Robotics US and Home Assistant Announce Integration to Bring the Power of Shelly Products to Smart Home Enthusiasts Allterco Robotics US and Home Assistant Announce Integration to Bring the Power of Shelly Products to Smart Home Enthusiasts LAS VEGAS, Dec. 14, 2020 Smart home innovator Allterco Robotics US, makers of the award-winning Shelly smart home products, and Home Assistant, an open source home automation platform, today announced a partnership that will seamlessly integrate all Shelly products. Home Assistant is the 10th largest open source project in the world today and the largest smart home specific open source project. By offering new native integration with Shelly, Home Assistant will be able to automatically detect and add any Shelly products which the user has installed. This seamless process enables user to configure the products however they would like for ultimate flexibility. For more informat ....
statistically significant vs. placebo or baseline (p 0.05) ^(p 0.08; 0.052) “There is a sizable overlap in the NASH patient population such that approximately 50% of NASH patients also have co-existing type 2 diabetes. PXL770 is one of the only therapies in development that has demonstrated the potential to treat NASH with specific use in patients with coexisting type 2 diabetes that are at higher risk for faster disease progression and for co-morbidities, including cardiovascular complications,” commented Pascale Fouqueray, MD, PhD, Executive Vice President, Clinical Development and Regulatory Affairs at Poxel. “AMPK activation has the potential to improve the underlying root causes of NASH, such as insulin resistance, the dysregulation of lipid and glucose metabolism and inflammation. We believe PXL770 has the potential to be a much-needed and differentiated therapeutic option for NASH and could be particularly important for the high-risk population with type 2 ....